Levetiracetam for Treatment-Refractory Posttraumatic Stress Disorder.
J Clin Psychiatry 2006;67(2):211-214
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To assess the use of levetiracetam,
a novel anticonvulsant agent, in the treatment of
refractory posttraumatic stress disorder (PTSD).
Method: Retrospective analysis was conducted of
23 patients with DSM-IV diagnosis of PTSD who,
after being deemed partial or nonresponders to
antidepressant therapy, received levetiracetam in a naturalistic
fashion. The primary outcome measure was the PTSD
Checklist-Civilian Version (PCL-C). Secondary outcome
measures included the Hamilton Rating Scale for Anxiety
(HAM-A), the Hamilton Rating Scale for Depression
(HAM-D), Clinical Global Impressions-Severity of Illness
scale (CGI-S), and Clinical Global
Impressions-Improvement scale (CGI-I).
Results: Levetiracetam at a mean ± SD dose
of 1967 ± 650 mg/day for 9.7 ± 3.7 weeks was generally
well tolerated. Nineteen patients (83%) were taking at least
1 concomitant medication. Patients were severely ill
with a mean baseline PCL-C score of 67.2 ± 9.4, CGI-S
score of 6.0 ± 0.7, and HAM-A score of 26.8 ± 4.9. Patients
improved significantly on all measures (p < .001).
Thirteen patients (56%) met responder criteria at endpoint
(PCL-C mean change = 23.5, CGI-I score < = 2), and 6
(26%) met remission criteria (CGI-S score < = 2).
Adverse events were generally mild, and no patients
discontinued levetiracetam because of side effects.
Conclusion: These preliminary data suggest
that levetiracetam may be an effective treatment in
combination with antidepressant therapy for patients with
PTSD who remain symptomatic after initial intervention.